A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission.


Journal Article

Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) clearly hastens myeloid recovery in patients with relapsed hematologic malignancies undergoing autologous bone marrow transplantation (ABMT). In efforts to further improve neutrophil engraftment and shorten hospital stay in ABMT patients, rhGM-CSF was administered by a potentially more potent route (continuous infusion) to non-Hodgkin's lymphoma (NHL) patients with better BM reserve (first remission). Time to myeloid engraftment was compared with that of NHL patients treated in first remission at our institution on a similar ABMT protocol but without growth factor support (controls). Median neutrophil engraftment (absolute neutrophil count, 500 cells/microL) in first remission patients treated with rhGM-CSF was 14 days, compared with 22 days in controls (P = .0001). Hospital stays were also significantly reduced for rhGM-CSF patients (P = .0003). Platelet engraftment did not differ between the two groups. Persistent fever and generalized serositis were the primary toxicities. rhGM-CSF, delivered by this route, was efficacious but more toxic than 2-hour rhGM-CSF infusions previously reported by other investigators. Future alterations in both dose and schedule may retain comparable efficacy yet diminish toxicity.

Full Text

Duke Authors

Cited Authors

  • O'Day, SJ; Rabinowe, SN; Neuberg, D; Freedman, AS; Soiffer, RJ; Spector, NA; Robertson, MJ; Anderson, K; Whelan, M; Pesek, K

Published Date

  • May 1, 1994

Published In

Volume / Issue

  • 83 / 9

Start / End Page

  • 2707 - 2714

PubMed ID

  • 8167349

Pubmed Central ID

  • 8167349

International Standard Serial Number (ISSN)

  • 0006-4971


  • eng

Conference Location

  • United States